```json
{
"content": [
{
"type": "paragraph",
"content": "The Sickle Cell Disease (SCD) Drug Market encompasses therapeutics targeting genetic disorders causing abnormal hemoglobin production, leading to chronic pain and organ damage. This market is critical for addressing a condition affecting over 100,000 individuals in the U.S. and millions globally, with 1 in 365 Black infants born with SCD. The Sickle Cell Disease Drug market size was valued at $4.1 billion in 2025, driven by approvals of novel therapies, rising prevalence, and advancements in gene editing. The growth outlook remains robust, with a projected CAGR of 12.5% from 2026–2033, supported by industry expansion in emerging markets and regulatory incentives."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Hydroxyurea", "Gene Therapy", "Other Therapies"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[12.0, 13.5, 14.0, 14.5, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5], // Hydroxyurea
[2.5, 3.0, 4.0, 5.0, 6.5, 8.0, 9.5, 11.0, 12.5, 14.0, 15.5, 17.0, 18.5], // Gene Therapy
[1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0] // Other Therapies
]
}
},
{
"type": "paragraph",
"content": "Key forces shaping the industry include advancements in CRISPR-based gene therapies (e.g., Casgevy and Lyfgenia approvals), regulatory tailwinds (FDA/Roche's Breakthrough Therapy Designations), and rising awareness in underdiagnosed regions like Africa and South Asia. North America holds the largest market share, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare access and SCD screening programs. Competitive intensity is escalating as biotech players partner with payers to address cost barriers for gene therapy adoption."
}
]
}
```
